Moors & Cabot’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Moors & Cabot’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-5,250	Closed	-$224K	–	748
2020 Q2	$224K	Sell	5,250 -649	-11%	-$26.8K	0.02%	546
2020 Q1	$214K	Buy	5,899 +2	+0%	+$85	0.03%	482
2019 Q4	$268K	Sell	5,897 -1,425	-19%	-$56.5K	0.03%	492
2019 Q3	$259K	Sell	7,322 -673	-8%	-$25K	0.03%	486
2019 Q2	$319K	Buy	7,995 +1,075	+16%	+$42.3K	0.04%	394
2019 Q1	$283K	Buy	6,920 +1,076	+18%	+$43.7K	0.04%	412
2018 Q4	$216K	Buy	5,844 +728	+14%	+$31.1K	0.03%	437
2018 Q3	$248K	Buy	+5,116	New	+$242K	0.03%	470

Other funds holding XPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

HCIA

Hochman Cole Investment Advisors Deerfield, Illinois $255M AUM 23.27% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

Moors & Cabot's XPH Position: Q3 2020 in Review

Moors & Cabot sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q3 2020, closing a stake of 5,250 shares — an estimated $224K sold.

Moors & Cabot first reported a position in XPH in Q3 2018 and held it in 8 quarters. The position peaked at $319K in Q2 2019. 72 funds tracked by Wall St. Rank hold XPH as of Q3 2020.

Moors & Cabot reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q3 2020 after selling out during the quarter.
Moors & Cabot sold 5,250 State Street SPDR S&P Pharmaceuticals ETF shares in Q3 2020, an estimated $224K.
Moors & Cabot first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q3 2018 and held it in 8 quarters.
Moors & Cabot's State Street SPDR S&P Pharmaceuticals ETF position peaked at $319K in Q2 2019.
72 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q3 2020.

Based on Moors & Cabot's 13F filing for Q3 2020, filed 9 Nov 2020.